# OnCo record folr1-expression (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/folr1-expression/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "folr1-expression" ;
  schema:name "Folate receptor alpha expression (FRα-positive, PS2+ >= 75%)"@en ;
  schema:alternateName "FRα"@en, "FRa"@en, "folate receptor alpha positive"@en, "FOLR1 expression"@en, "FRα-positive"@en, "PS2+ >= 75%"@en, "FOLR1 IHC"@en ;
  schema:description "Folate receptor alpha is a surface protein on most high-grade serous ovarian cancers. Mirvetuximab soravtansine requires FRα-positive disease, scored as at least 75 percent of cells with moderate or strong staining on the Ventana FOLR1 assay."@en ;
  schema:url <https://onco.cc/biomarkers/folr1-expression/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00c424b5-6ccd-48ab-9e88-1986451120e2> ;
  onco:tag "biomarker", "surface-antigen" ;
  onco:related <https://onco.cc/biomarkers/brca-somatic/>, <https://onco.cc/biomarkers/hrd-positive/> ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/platinum-resistant-ovarian-cancer/>, <https://onco.cc/cancers/high-grade-serous-ovarian-cancer/>, <https://onco.cc/cancers/endometrial/> ;
  onco:drugs <https://onco.cc/drugs/mirvetuximab-soravtansine/> ;
  onco:terms <https://onco.cc/terms/ihc/>, <https://onco.cc/terms/platinum-sensitivity/> .